Our Mission
Our Mission
To develop accessible, high-performance diagnostic tools that improve detection accuracy and support modern laboratory workflows.
Precision Immunoassays for Modern Laboratories
Advancing Diagnostic Precision
High-performance immunoassays for speed, specificity, and scalability.
Who We Are
About Synvitta Diagnostics
A biotechnology company dedicated to advancing modern diagnostic solutions through precision-engineered biomarker systems.
Founded in Florida, Synvitta combines scientific rigor with practical laboratory integration to develop high-performance immunoassays designed for clinical use and scalable deployment.
Our work focuses on improving analytical specificity, reducing assay time, and enabling seamless transition from singleplex to multiplex platforms.
Our Vision
Our Vision
To become a reference in precision diagnostics through innovative biomarker engineering and scalable assay design.
Innovation
Technology Platform
Synvitta develops high-precision immunoassays designed for scalable multiplex diagnostics. Our technology platform integrates optimized detection methodologies and advanced assay architectures to enable accurate, rapid, and cost-effective clinical testing.
The platform is engineered to support simultaneous detection of multiple biomarkers while maintaining high analytical performance and compatibility with standard clinical laboratory workflows.
Key capabilities
- High analytical specificity and sensitivity
- Rapid assay turnaround for clinical workflows
- Multiplex detection of multiple biomarkers in a single assay
- Scalable assay architecture compatible with clinical laboratories
- Future-ready integration of synthetic biomarker engineering
Products
Diagnostic Solutions
SynTREP™
Rapid Syphilis ELISA
SynTREP™ is a rapid ELISA assay developed for the detection of total antibodies to Treponema pallidum, the causative agent of syphilis.
- Consistent performance – The assay is designed to provide reliable and reproducible results while maintaining compatibility with standard ELISA laboratory workflows.
- Streamlined protocol – Optimized protocol enables efficient laboratory processing with a streamlined assay procedure.
- First Synvitta diagnostic solution – SynTREP™ represents Synvitta's first commercial diagnostic solution and is designed to support laboratories seeking rapid and accurate serological testing.
Key Features
- Rapid assay time (~1h15)
- Detection of total antibodies to Treponema pallidum
- High analytical sensitivity and specificity
- Streamlined ELISA workflow
- Compatible with standard ELISA laboratory equipment
- Designed for scalable laboratory testing
Applications
SynTREP™ can be used for:
- Research laboratories studying syphilis serology
- Assay development and validation studies
- Laboratory research workflows involving treponemal antibody detection
Assay Information
- Assay format
- 96-well ELISA microplate
- Detection method
- Colorimetric ELISA detection
- Assay time
- Approximately 1 hour 15 minutes
- Sample type
- Human serum or plasma
- Technology
- Immunoassay – ELISA format
Regulatory Status
Research Use Only (RUO)
This product is intended for research use only and not for use in diagnostic procedures unless otherwise authorized by regulatory authorities.
For pricing, technical information, or partnership inquiries, please contact the Synvitta team.
Our Team
Meet the Synvitta Team
Behind every assay and platform is a multidisciplinary team of scientists, clinicians, and operators dedicated to advancing diagnostic precision.
Leadership
Mitch Glaeser
Co-Founder & Chief Executive Officer
Rainara Almeida
Co-Founder & Chief Scientific Officer
Jefferson Bonavita
Vice President
Science & Technology
Lacey Nieves
Associate Scientist, Diagnostics R&D
Carlos Ivanski
AI & Data Science Engineer
R&D
Pipeline Development
Expanding Synvitta's diagnostic portfolio through scalable biomarker platforms and multiplex immunoassay technologies designed for clinical laboratory integration.
Research
Neurodegenerative Diseases
Neurodegenerative Diseases
Biomarker discovery and assay development focused on enabling early detection and improved monitoring of neurodegenerative diseases.
Research
Autoimmune Diseases
Autoimmune Diseases
Development of multiplex immunoassay platforms for detection and monitoring of immune-mediated disorders.
Development
Infectious Diseases
Infectious Diseases
Development of high-performance immunoassays designed for rapid, scalable infectious disease diagnostics.
Future Platforms
Precision Biomarker Engineering
Precision Biomarker Engineering
Development of synthetic peptide ligands and engineered biomarkers designed to improve diagnostic specificity and enable next-generation multiplex diagnostic platforms.